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Influenza is one of the most common infectious diseases that is preventable by 
vaccines yet causes high morbidity and mortality rates globally. It is prevalent 
worldwide and follows a clear seasonal pattern in temperate countries, which is not 
observed in tropical regions. It poses a significant public health concern and causes a 
remarkable disease burden globally. The ability of the virus to undergo antigenic shift 
and drift enables it to escape from host immunity and eventually leads to epidemics 
and pandemics. The availability of antiviral drugs and influenza vaccination may not 
fully prevent epidemic and pandemic from occurring due to the poor efficacy of the 
said drugs, the emergence of drug resistance and vaccine mismatches. Accurate 
prediction of the upcoming influenza strain is needed for effective prevention of 
influenza infection through vaccination. 
Adaptive host immunity plays an important role in protection against influenza 
infection and is mediated by several mechanisms. All current vaccines work 
principally through inducing virus-specific antibodies to mediate the protective effect 
of the vaccines. However, it has been documented that these antibodies decay 
overtime, hence global pharmaceutical industry channels money into developing 
adjuvant development-formulations that elicit cytotoxic T-cell responses which is 
more robust than antibody-based immunity.  
The objectives of this thesis are hence to investigate: 1) the trajectory of antibody 
decline following a seroconversion event to A(H1H1)pdm09 and 2) the role of pre-
existing T-cell mediated immunity to A/Singapore/CDC204/2012(H3N2) in 
protecting against subsequent  influenza infections, accounting for potential 
confounders such as age and recent vaccination. 
In chapter 2, we assessed the decline in influenza-specific antibody titres with a 
cohort of 67 adults who previously seroconverted to A(H1N1)pdm09. The rate of 
 vii 
 
antibody decline following seroconversion was monitored with 2 additional study 
timepoints. A(H1N1)pdm09-specific antibodies were quantified by  
Hemagglutination inhibition (HI) and microneutralization (MN) assays. The 
proportion sero-positive for influenza (HI≥40) decreased significantly from 71% to 
25% and 14% after half and one year respectively. The decline was more rapid in the 
elderly, possibly as a consequence of immunosenescence. These findings provided a 
motivation for the study in chapter 3 to explore an alternative protection strategy, 
which is especially crucial for the elderly.  
In chapter 3, a community cohort (n=507) was recruited to study the effect of baseline 
T-cell mediated immunity towards A/Singapore/CDC204/2012(H3N2) on subsequent 
influenza infections. Questionnaires and blood samples were obtained from 
participants, with influenza-specific antibodies quantified by HI and T-cell mediated 
quantified by ELISPOT assays. A significant protective effect was observed for both 
influenza infection with and without self-reported respiratory symptoms; the 
protective effect was more evident in participants with lower antibody titres, and 
became weaker over time from when the T-cell response was measured, suggesting 
that T-cell immunity to influenza also wanes, as has also been demonstrated for 
antibody mediated immunity. 
In conclusion, a more effective vaccination strategy is needed for protection against 
influenza infection since baseline influenza-specific antibodies were not a reliable 
protection mechanism against influenza infection. Pre-existing T-cell mediated 
immunity was shown to confer cross-protection for symptomatic and asymptomatic 
influenza infections; more work is needed to investigate their role and devise 
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CHAPTER 1. INTRODUCTION 
1.1 Background on influenza 
Influenza viruses pose significant public health concern and cause pandemics and 
epidemics. High mortality rates, such as that from the Spanish Flu pandemic in 1918 
which caused up to 50 million deaths, have been recorded in historical pandemics 
(Patterson & Pyle, 1991). Figure 1.1 shows the timeline of history of influenza 
pandemics and the relative mortality rates.  There is also a substantial burden of 
severe illness from epidemics of seasonal influenza. Seasonal influenza infection 
accounts for a great number of hospitalizations and excess death annually (Dushoff, 
Plotkin, Viboud, Earn, & Simonsen, 2006; Ortiz et al., 2014); for instance, it has been 
estimated that approximately 1,000 intensive care unit admissions and between 3,000 
and 9,000 excess all-cause deaths occur in England during winter seasons (Hardelid, 
Pebody, & Andrews, 2013), and 200,000–300,000 hospitalizations occur every year 
in the USA (Zhou et al., 2012) due to influenza. In Singapore, Lee and colleagues 
have also shown that excess mortality in Singapore during post-war period are highly 
correlated to influenza epidemics (V. J. Lee et al., 2009). Influenza has also been 
noted to be one of the vaccine-preventable diseases where the annual mortality rate 
remains high (Parkins, McNeil, & Laupland, 2009; Schaffner, 2008). 
Figure 1.1. Influenza pandemic timeline of the 20th and 21st centuries. The 
timeline depicts the pandemics of human influenza, with statistics showing the 




Influenza is a single-stranded, negative-sense RNA virus that belongs to the family 
Orthomyxoviridae (Bouvier & Palese, 2008). It has symptoms such as fever, 
headache, muscle aches, coughing, sneezing and other acute respiratory illnesses, and 
hence is commonly mistaken for the common cold (Eccles, 2005). There are three 
types of influenza virus, namely Influenza A, B and C. The subtypes of the Influenza 
A virus are dependent on the antigenic determinants Hemagglutinin (HA) and 
Neuraminidase (NA) present on its outer coat. Influenza A virus is the most virulent 
(Kidd, 2014) of all subtypes due to its ability to undergo antigenic drift and shift. An 
antigenic drift is the gradual mutation of the viral genome which causes a structural 
change in the virus which results in the formation of new viral strains, while an 
antigenic shift is a viral genetic variation process due to recombination of genetic 
material during co-infection of two viral strains and occurs infrequently (Brown, 
2000). Antigenic drift and shift give rise to new influenza strains where most 
individuals would not have pre-existing antibodies that protect against the infections, 
and may hence result in epidemics or pandemics. 
It has been proposed that the changing nature of the antigenic properties of influenza 
virus and its interaction with host populations results in the epidemiological patterns 
observed (Boni, Gog, Andreasen, & Feldman, 2006). Understanding the 
epidemiological patterns of influenza is crucial for the control of influenza in a 
country (Moorthy et al., 2012). In temperate regions, influenza typically arrives with 
the onset of cold weather (Moorthy et al., 2012). For instance, in the USA and other 
temperate countries, influenza epidemics are observed to follow a seasonal cycle 
(Reichert et al., 2004); complications and mortality may result from an influenza 
infection, and hospitalization rates spike during wintertime (von Klot, Zanobetti, & 
Schwartz, 2012). On the other hand, various patterns of influenza epidemics have 
been observed in tropical and sub-tropical countries; influenza viruses may circulate 
all year round, peak during rainy seasons, or not follow a seasonal pattern (Beckett et 
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al., 2004; Chow, Ma, Ling, & Chew, 2006; Moura, Perdigao, & Siqueira, 2009; 
Nguyen et al., 2007; Rao & Banerjee, 1993; Tsai, Kuo, Liu, & Wang, 2001).  
Influenza virus spreads from person-to-person by close contact and small-particle 
aerosols generated from infected individual through coughing and sneezing (Tellier, 
2006). Upon infection, it takes approximately 48 hours for the virus to replicate 
before symptoms are observed in the infected individual (Hermesh, Moltedo, Lopez, 
& Moran, 2010). During this period, virus shedding from an infected individual 
allows the transmission of the virus to another susceptible individual (Carrat et al., 
2008). However, a cohort study by Lau et al demonstrated that viral shedding may 
take place as early as before the appearance of symptoms and in asymptomatic 
individuals (Lau et al., 2010). 
 
1.2 Influenza genotype and morphology 
Different influenza subtypes and strains may infect different species depending on the 
sialic acid receptors present on the virus hemagglutinin (Couceiro, Paulson, & Baum, 
1993). Influenza A and C can infect human, avian and other mammalian species, 
while influenza B virus infects almost only humans (Hay, Gregory, Douglas, & Lin, 
2001). Influenza A viruses comprise a large variety of antigenically different strains 
determined by the hemagglutinin (HA) and neuraminidase (NA) present on the viral 
outer coat. To date, there is a total of 18 different HAs and 11 NAs, from which 
different combinations result in different virus strains (Tong et al., 2013). Of the 18 
different HAs, H1 to H3 are human influenza strains that have been circulating in the 
human population for the longest; the genetically newer strain variant either co-
circulates or replaces the previous circulating strain (Hay et al., 2001). Influenza A 
H3N2 is currently considered the most virulent subtype in terms of the severe illness 
and hospitalization cases that it has caused over the past few decades (Hay et al., 
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2001; Simonsen, Fukuda, Schonberger, & Cox, 2000). Influenza A H1N1 caused two 
pandemics in the past one hundred years with A(H1N1)pdm09 having a 
comparatively lower mortality rate than the Spanish Flu pandemic in 1918 (Franco-
Paredes et al., 2009).  
The influenza virion is a globular particle of about 50-120 nm in diameter and its 
genome consists of eight RNA segments (Bouvier & Palese, 2008). These eight 
segments code for 11 proteins, namely the HA, NA, M1, M2, NP, PB1, PB1-F2, PB2, 
PA, NS1 and NS2 proteins (Brown, 2000). Knowledge of the morphology of the 
Influenza virus aids in the development of effective treatments against the infection. 
However, drug and vaccine development is a challenging process and the modes of 
conventional treatment currently available in the market do not provide long-lasting 
protection against influenza infection.  
 
1.3 Conventional prevention and treatment and their limitations 
Conventional prevention and treatment for influenza infection includes vaccination 
and antiviral drugs (Rowe, Ng, Chandra, Chen, & Leo, 2014). Vaccination involves 
injecting individuals with inactivated or attenuated viruses carrying a specific epitope 
to initiate an immune response in the body while antiviral drugs are specific 
chemicals that affect the viral life cycle at a particular stage(s). There are 2 classes of 
anti-influenza drugs available in the market; the Adamantanes (M2 ion channel 
inhibitors: Amantadine and Rimantadine) and the Neuraminidase inhibitors: 
Zanamivir and Oseltamivir (Beigel & Bray, 2008). However, the effectiveness of 
conventional vaccines and even antiviral drugs can be negated by the ability of the 
virus to constantly mutate (Meiklejohn, Eickhoff, Graves, & I, 1978). Frequent 
mutations (antigenic drifts) and recombination events (antigenic shift) occur in the 
viral genome, allowing the virus to evade host immune responses (from vaccination 
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or prior natural infection) as well as develop resistance towards antiviral drugs 
(Moscona, 2005; Tria, Pompei, & Loreto, 2013). 
Current influenza vaccination mostly provides humoral immune protection (Amanna 
& Slifka, 2011; Couch, 2008) against infection from a particular predicted 
combination of influenza subtypes. Accurate prediction of the subtype causing the 
next probable influenza outbreak has to be made before the development of a vaccine 
that targets that particular subtype. However, vaccine mismatch is not uncommon due 
to the unpredictability of influenza virus. Furthermore, the vaccine developmental 
process requires a period of six to nine months, not including the time needed to 
pinpoint a targeted subtype, during which the selected viral strains are cultivated in 
embryonated chicken eggs (Wong & Webby, 2013). By the time a vaccine targeting a 
particular subtype has been developed, the virus may have mutated into a different 
strain that is resistant to the vaccine, hence rendering it ineffective.  
On the other hand, it is uncertain how long current conventional antiviral drugs will 
continue to be effective against circulating influenza virus strains. Some strains have 
already developed resistance against them, through constant mutations (Boivin, 
2013). Viral resistance has been observed in both classes of anti-viral drugs, with 
lesser resistance in the Neuraminidase inhibitors than M2 ion channel inhibitors (H. 
K. Lee et al., 2015). Also, even in the absence of drug resistance towards Zanamivir 
and Oseltamivir, these agents have other limitations. Administration of the drug has 
to be made within 48 hours after the onset of the symptoms for the maximum 
effectiveness of the drugs (Cooper et al., 2003; Rowe et al., 2014). There is thus an 






1.4 Host adaptive immune response against influenza virus infection 
Human immunity to viral infection is divided into the innate and adaptive arms. 
Innate immunity is the first line of defense against influenza virus infection while 
adaptive immunity forms the second line of defense which is more specific than 
innate immunity. The adaptive immunity comprises of humoral and cellular (or cell-
mediated) immunities mediated by virus-specific antibodies and T-cells respectively 
(Kreijtz, Fouchier, & Rimmelzwaan, 2011).  
Humoral immunity against influenza viruses can be induced by vaccination or 
infection with influenza virus. Influenza-specific antibodies to the surface 
glycoproteins HA and a lesser extent to NA are produced to neutralize the virus by 
inhibiting entry of virus into host cells (Kreijtz et al., 2011). Presence of antibodies 
recognizing HA is an important correlate of protection if the antibody matches the 
virus causing the infection (Couch & Kasel, 1983; Hobson, Curry, Beare, & Ward-
Gardner, 1972). Recent development in HA molecule research have also identified 
antibodies binding to the more conserved epitopes in the stem region of HA instead 
of globular head of the HA molecule exhibit broad neutralizing capacity (Ekiert et al., 
2009; Ekiert et al., 2011; Sui et al., 2009). Memory B-cells against a specific 
influenza strain would develop after an infection; therefore the quantity of influenza-
specific antibody can be measured by serologic assays such as the hemagglutination 
inhibition (HI) assay or the microneutralization (MN) assay. These two assays exploit 
the specificity of the antibody’s receptor binding ability to quantify the influenza-
specific antibodies to be measured. HI assay remains the gold standard assay for 
measuring the quantity of virus-specific antibodies; the antibody binds and 
agglutinates red blood cell (RBC) added to the HI assay. It is widely used in most 
influenza research and is employed in influenza vaccine development (Barr et al., 
2014). MN on the other hand is a more direct method to quantify virus-specific 
antibodies – it is performed by adding a specific virus into the assay for neutralization 
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by the virus-specific antibody to be quantified (Katz, Hancock, & Xu, 2011). 
However, it is more labour and time intensive as compared to the HI assay (Grund, 
Adams, Wahlisch, & Schweiger, 2011). 
Cell-mediated immunity against influenza virus consists of mainly the CD4+ and 
CD8+ T-cells. CD4+ T-cells are activated when major histocompatibility complex 
MHC class II-associated peptides on antigen presenting cells (APCs) are recognized. 
Activated CD4+ T helper cells promote B cell response in producing influenza-
specific antibodies (Lamb, Woody, Hartzman, & Eckels, 1982). The main function of 
influenza-specific CD8+ T-cells is that of cytotoxic T lymphocytes (CTL). Influenza 
infected cells are recognized and cleared by cytotoxic CD8+ T-cells via the major 
histocompatibility complex (MHC) class I presentation of viral antigen. Interferon-
gamma (IFN-γ) is also produced in the process to enhance the antigen-presentation by 
stimulating MHC expression (Schoenborn & Wilson, 2007). Hence, IFN-γ serves as a 
good measurement of T-cell mediated immunity during an influenza infection. The 
quantity of IFN- γ produced can be measured by ELISPOT assay. 
 
1.5 Rationale for this thesis 
However, despite the protection conferred by the body’s immune system, an 
individual’s health may still be compromised by an influenza viral infection. The host 
immune system recognizes the virus by viral epitopes, and synthesis of antibodies 
would only start when the presence of viral epitope is detected in the body. However, 
due to the immune selection pressure in the human population and the high-mutation 
rate of influenza viral binding epitopes, antigenically distinct influenza viruses may 
arise which are not recognized by existing adaptive immune system (Kreijtz et al., 
2011). Given that the development of a full-fledged strain-specific immune response 
towards a novel strain is not immediate and requires approximately six to twelve days 
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(Hermesh et al., 2010; Janeway, Travers, Walport, & J., 2001), the virus would have 
time to proliferate and symptoms and even severe disease might develop.  
In addition, even though memory cells have the capacity of mounting an immune 
response almost immediately after an infection, pre-existing antibodies may decline 
after some time. In our previous research, we have observed a decline in pre-existing 
antibodies towards the A(H1N1)pdm09 at a population level titre (Chen et al., 2013) 
following the initial wave of influenza A(H1N1)pdm09 infections in Singapore. This 
suggests that pre-existing antibodies generated from either natural infection or annual 
influenza vaccination might decrease with time. In the case of vaccination, the time 
between vaccination and an epidemic might affect vaccine efficacy, which makes this 
a public health concern. There is hence a need to estimate the rate of decline of 
antibody mediated immunity and how this might affect vaccination strategies, 
particularly in the tropics where the unpredictable seasonality of influenza makes it 
far more difficult to schedule vaccinations just before epidemic periods. 
Furthermore, it is well established that immune senescence is associated with the 
increased susceptibility to infectious diseases and decreased vaccine efficacy in the 
elderly (McElhaney, 2011). When protection against influenza infection is dependent 
on influenza-specific antibodies, it is essential to have proper B-cell function that 
generates effective antibody response upon influenza infection or vaccination (Liu, 
van der Zeijst, Boog, & Soethout, 2011). However, decrease in naïve B-cell 
generation is observed in the elderly, which may also impact the ability of their 
immune system to mount an effective immune response against influenza infection 
(Allman & Miller, 2005). Such decline in immunity in the elderly would also affect 
the effectiveness of the immune response generated by influenza vaccination and 
influenza antibody kinetics; if so, it would imply a need for alternative approaches to 
vaccination against influenza. 
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Recent developments in influenza vaccine research have found that T-cell mediated 
immunities may be a more promising candidate for broadly protective vaccines, as T-
cells target protein epitopes that are highly conserved between different subtypes for 
influenza viruses (Altenburg, Rimmelzwaan, & de Vries, 2015), reduce the severity 
of influenza illness (Sridhar et al., 2013). Pre-existing T-cell mediated immunity is 
also considered to be a better correlate of protection for the elderly than pre-existing 
antibodies (McElhaney et al., 2006). It is hence important to determine if T-cell 
mediated immunity can indeed confer protection independent of antibody mediated 
immunity across different age groups.  
 
1.6 Aim and hypotheses of thesis projects 
This thesis investigates, at the individual-level, interactions between influenza and 
host immunity. Firstly, we aimed to establish the degree of decline of influenza-
specific antibodies in the humoral arm of host immunity, and also determine if the 
decline was more rapid in any particular subgroups, in particular older individuals. 
Secondly, we investigated the possible protection that may arise from the T-cell 
mediated responses in the cellular arm of host immunity.  
Both investigations were carried out using prospective cohort study designs, where an 
individual was followed up over a study period to obtain relevant information and 





CHAPTER 2. STUDY OF ANTIBODY DECLINE IN GENERAL 
COMMUNITY COHORT  
2.1 Background of the study  
Recurrent epidemics of influenza occur in winter in temperate climates, whereas in 
Singapore and other tropical areas, influenza activity is observed all year round with 
less predictable peaks of activity (Bloom-Feshbach et al., 2013; V. J. Lee et al., 
2009). Following the emergence of pandemic influenza A(H1N1)pdm09 in March 
2009, it was estimated that between 17–31% of participants in a multi-country study 
were seropositive after the initial epidemic of infections (Trauer et al., 2013). Despite 
this, multiple epidemics of infection with the same virus subsequently occurred in 
Singapore and elsewhere in late 2009 and 2010 (Chen et al., 2013; Presanis et al., 
2011), with some evidence of shifts in age distribution to involve older individuals 
(Mytton, Rutter, & Donaldson, 2012; Win et al., 2011). 
The ability of the influenza virus to undergo antigenic drift by its frequent mutations 
allows it to cause re-infections of the same individual, and also provides one 
explanation for recurrent epidemics from different strains of the same influenza 
subtype, thus necessitating frequent updates of influenza vaccines to ensure optimal 
match between the vaccine and prevailing influenza strains (Brown, 2000). However, 
one modelling study suggests that loss of immunity to the same strain also represents 
an important mechanism underlying the epidemiology of seasonal influenza (Truscott 
et al., 2012). One empirical study has shown a decline in antibody titres, with only 
52% of naturally infected and 34% of vaccinated individuals having HI titres of ≥ 40 
after 6 months of follow-up (Wang et al., 2011). However, another smaller study 
including both naturally infected and vaccinated individuals reported a less dramatic 
decrease, with only about 5% showing a 4-fold or greater decline in antibody titres 
after approximately one year by both HI and virus MN assays (Chan et al., 2011). 
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Given such discrepant findings, more studies are needed to clarify the proportions of 
individuals still having HI titres of ≥ 40 (which is often considered as the threshold 
for a seroprotective response) (Al-Khayatt, Jennings, & Potter, 1984; Papenburg et 
al., 2011), as well as the rate of decline within the period from 6 months to 1 year 
following seroconversion. Insights are also needed on whether the findings differ 
when using HI and MN assays. In addition, several cohort studies have suggested that 
a substantial proportion of influenza infections are asymptomatic (Chen, Lee, et al., 
2010; Hayward et al., 2014; Horby et al., 2012; Riley et al., 2011), but it is unclear if 
the immune responses in such infections are as robust and durable as those observed 
in symptomatic influenza. There are also questions, given our observations 
supporting immune senescence in the elderly (Allman & Miller, 2005; Liu et al., 
2011), if the rate of decline differs by age. 
This study aimed to determine the possible waning of post-infection antibodies by 
quantifying the rate of decline in a cohort of individuals who seroconverted to 
A(H1N1)pdm09, and were followed up at two additional time-points, i.e. 
approximately 6 months and 1 year after seroconversion. The study also estimated the 
proportions with different antibody titres by both HI and MN assays, and explored if 
there were differences by age, gender and symptoms, as well as how estimates of 
seroconversion may be affected by longer intervals between serological samples in 





2.2 Materials and Methods 
2.2.2 Study Design 
Participants in this study were a subset of our previous cohort study, and comprised 
individuals aged 21 to 75 years from the multi-ethnic cohort of the Singapore 
Consortium of Cohort Studies (Chen, Lee, et al., 2010). In our previous study, each 
participant contributed a baseline pre-epidemic sample (obtained between June 2005 
to June 2009) and up to two follow-up samples to determine whether they 
seroconverted to A(H1N1)pdm09 from June to October 2009, when Singapore 
experienced the initial epidemic of A(H1N1)pdm09 infections. All participants from 
the original study who consented to continue participation contributed additional 
blood samples between April and September 2010, as well as answered a 
questionnaire survey administered concurrently (Chen et al., 2013). The subset of 
participants who seroconverted (defined as a four-fold or greater increase in titres 
between any two successive samples by HI assays) to A(H1N1)pdm09 between June 
and October 2009 was selected to investigate subsequent antibody kinetics in later 
samples. Participants who reported receipt of influenza vaccine after October 2009 
(which would have contained the pandemic A/California/7/2009 strain) were 
excluded, since this would have altered the subsequent trajectory of antibody titres. 
For each participant, blood sample with the highest HI titre in 2009 was chosen, 
which would have been taken (between 20 to 29 August 2009) about 3 weeks after 
incidence had peaked during the initial epidemic of A(H1N1)pdm09 infections in 
Singapore, or (between 6 to 11 October 2009) when the epidemic had clearly ended. 
This was used as a reference point (designated as Sample A), both to detect 
seroconversion from pre-epidemic samples, as well as to investigate how titres 




•Sample B collected from 8 to 22 April 2010, about 6 to 8 months after sample A. 
•Sample C collected from 19 to 27 September 2010, approximately 6 months after 
sample B (and more than 12 to 14 months after sample A). 
Finally, we also investigated how any decline in antibody titres might affect the 
proportion of seroconversions detected had we used longer intervals between 
sampling time-points, by computing the number with 4-fold or greater rise in titres 
when independently comparing samples B and C against the pre-epidemic sample 
taken before the initial epidemic of infections which started in mid-June 2009.  
 
2.2.3 Laboratory procedures 
2.2.3.1 Serum Isolation from Blood 
Approximately 10 ml of whole blood sample was collected in plain tube and it was 
spun down at 1500 rcf for ten minutes to obtain serum. Serum was then aliquoted and 
stored in -80oC until assayed.  
HI assays for the pre-epidemic sample and sample A were performed as a single 
batch of tests in November 2009 as part of our earlier study on the sero-incidence of 
A(H1N1)pdm09 during the initial epidemic of infections in Singapore (Chen, Lee, et 
al., 2010). Samples B and C were batch-tested by HI in December 2010 as part of our 
follow-up study on subsequent epidemics of A(H1N1)pdm09 in 2010 (Chen et al., 
2013). The MN assays were conducted in November 2011, as alternative means of 






2.2.3.2 Hemagglutination Inhibition (HI) Assay 
For HI assays, serum samples were pre-treated with receptor destroying enzyme 
(RDE [II], Deka Seiken Co Ltd, Tokyo, Japan), 1:4 (vol/vol), at 37°C for 16 hours, 
before enzyme inactivation by the addition of an equal volume of 1.6% trisodium 
citrate (Ajax Chemicals, Melbourne, Australia) and incubation at 56°C for 30 
minutes. 
HI assay was performed according to standard protocols at the World Health 
Organization (WHO) Collaborating Centre for Reference and Research on Influenza 
in Melbourne, Australia (Kendal, Pereira, Skehel, & others, 1982). Two-fold serial 
dilutions were first performed on the treated serum in 96-well V-bottom microtiter 
plates. Egg-grown A/California/7/2009 A(H1N1)pdm09 pandemic virus was purified 
by sucrose gradient, concentrated and inactivated with β-propiolactone, to create an 
influenza zonal pool preparation (a gift from CSL Limited, Melbourne, Australia). 
Twenty-five microliters (4 hemagglutination units) of influenza zonal pool-
A/California/7/2009 virus was incubated at room temperature with an equal volume 
of RDE-treated serum. Serum samples were titrated in 2-fold dilutions in phosphate-
buffered saline from 1:10 to 1:1280. Following 1 hour of incubation, 25 μL of 1% 
(vol/vol) turkey red blood cells was added to each well. Hemagglutination inhibition 
was read after 30 minutes. Titres were expressed as the reciprocal of the highest 
dilution of serum where hemagglutination was prevented. We defined seroconversion 
as a 4-fold or greater increase in antibody titres. 
 
2.2.3.3 Microneutralization (MN) assay and Basic Local Alignment Tool (BLAST) 
MN assays were performed at the National University of Singapore using pandemic 
influenza A/Singapore/GP2651/2009 virus isolated in Singapore during the initial 
epidemic of A(H1N1)pdm09 infections, which has been used in MN work since the 
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latter half of 2009 (V. J. Lee et al., 2010). BLAST analyses to compare the sequences 
of the HA and NA of the two A(H1N1)pdm09 strains (i.e. A/California/7/2009 and 
A/Singapore/GP2651/2009) revealed nucleotide and amino acid identities of 96-98%, 
thus confirming their strong homology. Madin-Darby canine kidney (MDCK) cells 
were seeded with Eagle’s minimum essential medium or EMEM (ATCC, Manassas, 
VA) in 96-well flat bottom plates and incubated for 24 hours at 37°C with 5% CO2 to 
obtain confluent monolayers. Two-fold serial dilutions of each serum sample were 
performed using EMEM starting with the 1:10 dilution. Equal volumes of 100 tissue 
culture infective dose (TCID50) of A/Singapore/GP2651/2009 virus (25 µl) and each 
serum dilution (25 µl) were incubated for 2 hours at 35°C with 5% CO2. The cells 
were washed thrice before adding serum-free medium containing 3 µg/ml of TPCK-
treated trypsin (Sigma-Aldrich, St Louis, MO), inoculated with the virus-serum 
mixtures, and then incubated for at 35°C with 5% CO2. Cytopathic effect (CPE) was 
observed for the next 72 hours. The neutralizing antibody titre was defined as the 
reciprocal of the highest serum dilution at which the infectivity of 100 TCID50 of 
virus for MDCK cells was completely neutralized in 50% of the wells. 
 
2.2.4 Statistical Analysis 
Geometric mean titres (GMTs) were estimated by assigning a value of 5 for titres 
below 10, and a value of 1,280 for titres of 1,280 or higher. A multinomial ordered 
probit model for the distribution of titres over three sampling periods was then 
developed to allow the rate of change in the distribution of HI and MN titres to be 
estimated. This formulation permitted age, gender, symptoms as well as interactions 
with sampling periods, to be adjusted for as potential confounders in the model. 
Individuals who had fever, sore throat, cough, nasal congestion or shortness of breath 
were classified as symptomatic infections, while those with none of these symptoms 
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were classified as asymptomatic infections. The likelihood of the data was derived 
using the following model: 
xij = k+1⋅ if ×zij ∈(θk,θk+1) 
zij ~ (μij,1) 
μij = βTwij+∈i 
where xij is the jth observed titre for the ith participant, zij is a latent variable, a 
propensity for high titres, and thresholds determining observations, μij controls the 
location of the latent variable to ensure identifiability, wij are individual-level 
covariates, ∈i is a random effect term, and θk are ordered thresholds. Markov chain 
Monte Carlo sampler was developed to integrate over the space of unobserved latent 
variables. 
Given that the HI assays were performed in two batches and possible intra-laboratory 
variation of HI titres between batches of replicate assays (Wood et al., 2012), a 
simple sensitivity analysis was conducted. All our statistical analyses were repeated 
based on the assumption that HI titres for samples B and C were up to 2-fold higher 
than what was measured, and assessed if this would have changed any of our main 
conclusions. 
All statistical analyses were performed using the R statistical software 3.0.0 (Institute 
for Statistics and Mathematics, Vienna, Austria). 
 
2.2.5 Ethics review  





2.3. Results  
Of the 838 participants originally enrolled, 727 had at least one additional follow-up 
blood sample, of which 98 seroconverted to A(H1N1)pdm09. Of the 98 participants, 
70 also contributed samples B and C (in April and September 2010). After excluding 
three participants who reported receipt of influenza vaccine between October 2009 
and September 2010, samples from 67 participants were left for analyses. Participants 
(30 males and 37 females) had a median age of 42.5 years (range 21 to 62 years), 
with 53 participants who reported symptoms. 
Four participants had a 2-fold increase in HI titre, and another four different 
participants had a 2-fold increase in MN titre between successive assays. As a 2-fold 
change can be considered to be within the margin of error for the respective assays, 
these observations were retained in subsequent analyses. However, one participant 
showed a 32-fold increase in HI and 16-fold increase in MN titres between samples A 
and B, while another showed an 8-fold increase in HI and 16-fold increase in MN 
titres between samples B and C. Since these two participants may have been re-




Figure 2.1 shows that titres from our HI and MN assays for samples A to C were 
strongly and significantly correlated (R-squared 0.45, P < 0.001), and that the degree 
of correlation did not vary by sampling period. A HI titre of 40 was approximately 
equivalent to a MN titre of 160, the former being a commonly referenced correlate of 
protection in immunological studies. Subsequent MN data was hence presented with 
reference to a positive cut-off titre of 160 and above. 
 
 
Figure 2.1 Scatterplot of titres from HI and MN assays. Random jitter was added 
to separate overlapping data points, and different symbols denote data from sample A 
(baseline) to sample C. The straight line in black is for the best fitting regression 






Figure 2.2 presents the observed (bars) and modeled (points) distribution of HI and 
MN titres from the multinomial ordered probit regression over the three sampling 
periods. It is noted that HI titres in particular are not normally distributed. The chosen 
model provides a reasonable fit to the data, with predicted 95% credible intervals 
overlapping with the observed distribution in almost all titre intervals. The model 
suggests that sampling periods are significantly associated with a negative change in 
titre by both HI and MN, as indicated by the negative posterior means with 95% 
credible intervals that are less than zero (Table 2.1). Female gender (by HI assay) and 
presence of symptoms (by both HI and MN assays) were also significantly associated 
with higher titre distributions. There was significant interaction between sampling 
period and age category, indicating that the older age group (≥55 years) showed a 
significant decrease in excess of what would be expected for the younger age group 




Figure 2.2 Model goodness of fit of a multivariate ordered probit model to 
antibody titre distribution. The bars represent HI assays (left column; Figures 2.2A, 
2.2C and 2.2E) and MN assays (right column; Figures 2.2B, 2.2D and 2.2F) at three 
time points in 2009 (Figures 2.2A and 2.2B), April 2010 (Figures 2C and 2D) and 
September 2010 (Figures 2.2E and 2.2F), with 95% confidence interval error bars. In 
black is the posterior predictive distribution (mean and 95% credible interval). The 
ordered probit model accounts for age and sex as potential confounders, along with 
individual random effects and a temporal decay in antibodies, and uses the same θ 
thresholds at all time-points. All the non-Gaussian distributions, and evolving shape 
of the distribution, are apparent, but the flexibility of the model formulation is able to 




Table 2.1: Results of posterior means with 95% credible intervals of individual-
level covariates estimated by the multinomial ordered probit model. The 
sampling period is significantly associated with a negative change in HI and MN 
titres as indicated by the negative posterior means and 95%CI less than zero. 
Factor 











Age ≥ 55 years  





Female (versus male)  1.37 (0.06, 2.71)  0.49 (-0.96, 1.98) 
Any symptoms  2.07 (0.38, 3.84)  3.53 (1.60, 5.55) 
Sample B (versus sample A) -2.96 (-4.24, -1.72) -0.90 (-1.95, 0.18) 
Sample C (versus sample A) -3.54 (-4.96, -2.19) -2.31 (-3.49, -1.15) 
     
Interaction terms     
Age ≥ 55 years with sample B -1.28 (-3.02, 0.40) -2.99 (-4.57, -1.46) 
Age ≥ 55 years with sample C -3.40 (-5.28, -1.57) -2.77 (-4.30, -1.26) 
Female with sample B -1.44 (-2.37, -0.50)  0.66 (-0.19, 1.50) 
Female with sample C -1.35 (-2.35, -0.37)  0.58 (-0.26, 1.46) 
Any symptoms with sample B -0.66 (-1.89, 0.55) -1.63 (-2.77, -0.54) 





There was also significant interaction between sampling period with gender by the HI 
assay, and with symptomatic infections by the MN assay. The effect of these 
interactions is illustrated in Figure 2.3, which models the mean HI and MN titres with 
95% credible intervals. While mean titres were slightly higher in the older age group 
in sample A by both HI and MN assays (Figures 2.3A and 2.3B respectively), the rate 
of decrease was also faster, such that the trajectory of the mean titres for the two age 
categories crossed by sample B, and the mean and spread of titres in sample C for 
those ≥ 55 years was lower than for those aged < 55. We observed that women and 
symptomatic infections had higher HI titres in sample A, but a marginally faster rate 
of decline (Figures 2.3C and 2.3E), so that titres were not substantially different by 
gender or symptoms in samples B and C. By MN, the trajectories of antibody decline 
for the two genders (Figure 2.3D) were essentially parallel, and while there was a 
slightly faster rate of decline from samples A to B, symptomatic infections continued 
to show marginally higher titres in samples B and C due to the substantially higher 






Figure 2.3 Modelled antibody trajectories by age category and gender on HI and 
MN assays. In orange is the posterior predictive distribution for individuals with age 
< 55 at three time points in 2009, April 2010 and September 2010, with 95% credible 
interval error bars (2.3A, 2.3B). In black is the posterior predictive distribution for 
individuals with age ≥ 55, with 95% credible interval error bars (2.3A, 2.3B). In blue 
is the posterior predictive distribution for males, with 95% credible interval error bars 
(2.3C, 2.3D). In pink is the posterior predictive distribution for women, with 95% 
credible interval error bars (2.3C, 2.3D). In red is the posterior predictive distribution 
for patients with any respiratory symptoms, with 95% credible interval error bars 
(2.3E, 2.3F). In grey is the posterior predictive distribution for patients without any 





Figures 2.4A and B illustrate the fraction which might be below putative cut-off 
points for seroprotection, both using our model and just the observed proportions. On 
the observed data, 71% of all subjects had HI titres ≥ 40 and 72% had MN titres ≥ 
160 in sample A, but the corresponding proportions were only 25% and 40% by 
sample B, and 14% and 37% by sample C. None of those aged ≥ 55 years had HI 
titres ≥40 or MN titres ≥ 160 in sample C, compared with 15% and 41% of those aged 
< 55 years (P = 0.58 and P = 0.08 respectively). Results from the modelled 
distribution were fairly similar, with confidence intervals overlapping those from the 
observed data.  
 
Figure 2.4 Estimated and observed proportions by age and sampling period for 
titres above respective cut-off points for (A) HI ≥40, and (B) MN ≥160. The bars 
with whiskers, which represent 95% confidence interval, indicate observed 
proportions stratifying by age and sampling periods. The black points with 95% 






With HI assays, using longer time intervals between sampling time-points 
substantially reduced the number of seroconversions detected. Only 27 and 23 
participants were found to seroconvert when comparing the titres in samples B and C 
to the pre-epidemic sample; i.e. only 42% and 35% of the 65 participants who 
seroconverted by HI with sample A. Of these 65, only 6 did not also seroconvert by 
MN assays between the pre-epidemic sample and sample A. Of the 59 who 
seroconverted, 56 (95%) were also assessed to have seroconverted between the pre-
epidemic sample and sample B, and 53 (90%) between the pre-epidemic sample and 
sample C. In the sensitivity analysis, even assuming that HI titres in samples B and C 
were up to 2-fold higher than what we measured, we found that there would be 
significant reduction in titres from samples A to B, and from A to C (Table 2.2). 
There were also no changes to any of the factors and interaction terms identified to be 
significant in the original regression analysis, and seroconversion could still be 
observed in 37 (57%) and 34 (52%) of the 65 individuals respectively when 




Table 2.2: Original analysis and sensitivity analysis for regression model on HI assay. 
Significant reduction in titres from sample A to samples B and C is present even when the 
the HI titres in samples B and C were assumed to be 2-fold higher than what was measured. 
Factor 
Coefficients in original 
analysis 
Coefficients in sensitivity 
analyses (assumed 

















Female (vs male)  1.37 (0.06, 2.71) 1.26 (0.01, 2.56) 
Any symptoms  2.07 (0.38, 3.84) 2.00 (0.46, 3.78) 
Sample B (vs sample A) -2.96 (-4.24, -1.72) -1.10 (-2.23, -0.01) 
Sample C (vs sample A) -3.54 (-4.96, -2.19) -1.58 (-2.80, -0.45) 
     
Interaction terms     
Age ≥55 years with Sample B -1.28 (-3.02, 0.40) -1.16 (-2.89, 0.41) 
Age ≥55 years with Sample C -3.40 (-5.28, -1.57) -3.19 (-5.04, -1.42) 
Female with Sample B -1.44 (-2.37, -0.50) -1.30 (-2.22, -0.42) 
Female with Sample C -1.35 (-2.35, -0.37) -1.19 (-2.11, -0.27) 
Any symptoms with Sample B -0.66 (-1.89, 0.55) -0.60 (-1.76, 0.55) 
Any symptoms with Sample C -0.53 (-1.84, 0.79) -0.56 (-1.73, 0.67) 
Significant results are given in bold font. 
 
Table 2.3: Original analysis and sensitivity analysis for seroconversion on HI assay. 
There was no change observed in the number of seroconversion when the titres in samples 
B and C were assumed to be 2-fold higher than what was measured. 
 Original analysis Sensitivity analysis (assume 
sample B and C are 2-fold higher) 
No. 
seroconverted 
% seroconverted No. 
seroconverted 
% seroconverted 
HI assay     
Sample B vs 
pre-epidemic 
27 41.5% 37 56.9% 
Sample C vs 
pre-epidemic  






The objective of the study was to investigate temporal changes in antibody titres 
following seroconversion during the initial epidemic of A(H1N1)pdm09 infections in 
Singapore. Although it is not a novel finding that antibody responses decreases 
overtime, our results revealed a considerably rapid decline in antibody titres 
following seroconversion, with only a fifth of those who originally had HI titres of ≥ 
40 and half of those with MN titres of ≥ 160 still having titres above the respective 
cut-off points after a year. There was also some indication that the rate of decline was 
higher in older individuals, and that the change in antibody titres measured by HI was 
greater than by MN. Symptomatic infections were associated with higher starting 
antibody titres, and continued to have marginally higher titres in subsequent samples, 
at least by MN assays. 
The cohort of participants who seroconverted between June and October 2009, were 
presumptively infected for the first time with A(H1N1)pdm09 during the initial 
epidemic in Singapore which peaked in early August 2009 (Ong et al., 2010). After 
its emergence, additional epidemics of A(H1N1)pdm09 were observed in Singapore 
and elsewhere (Chen et al., 2013; Mytton et al., 2012), and mortality records suggests 
that similar phenomena occurred in past pandemics (V. J. Lee et al., 2007). Since 
lower antibody titres do correlate with increased susceptibility to some extent (Couch 
et al., 2013), the subsequent decline in antibody titres in this cohort offers one 
possible explanation for re-infections, as well as for recurrent epidemics of 
A(H1N1)pdm09 in Singapore between November 2009 to February 2010, and April 
to June 2010 (Chen et al., 2013). On the other hand, there was less epidemic activity 
A(H1N1)pdm09 in Singapore after 2010 (see Fig 3.1C), and the full picture may thus 




The findings also have implications for the use of influenza vaccines. Other studies 
found that vaccination against A(H1N1)pdm09 may induce a weaker response than 
natural infection (Chan et al., 2011), and that HI titres decrease significantly in both 
naturally infected and vaccinated subjects after 6 months (Wang et al., 2011). Our 
previous study on A(H1N1)pdm09 infections confirmed by RT-PCR showed that the 
proportion with HI titres of ≥ 40 remained reasonably constant in samples collected 
up to 2 months post-infection, but that a reduction in GMTs was just about to become 
apparent by then (Chen, Barr, et al., 2010). In combination with findings from this 
study, it would suggest the most rapid decrease may be occurring between 2 to 6 
months after antibody titres peak, with a less marked decline in the window between 
6 months to 1 year. If antibody decline in vaccinated subjects indeed follows what we 
observed in natural infections, then influenza vaccine should be given within 6 
months of anticipated exposure. 
While this is typically the case in temperate countries, the year-round risk of infection 
in the tropics (V. J. Lee et al., 2009) makes this a much more challenging prospect, 
and may require more frequent vaccination schedules. In addition, the faster rate of 
decline in the elderly may exacerbate the above issues with vaccination. 
Notwithstanding the small number of elderly subjects in our study, the results are 
consistent with previous understanding on how aging influences the magnitude and 
quality of the humoral immune response by affecting both the size and diversity of 
the B-cell repertoire and antibody affinity (Weinberger & Grubeck-Loebenstein, 
2012). A more rapid decline of specific immunity following vaccination may also 
account for observations on the questionable efficacy of influenza vaccine in older 
compared to younger individuals (Osterholm, Kelley, Sommer, & Belongia, 2012; 
Simonsen, Taylor, Viboud, Miller, & Jackson, 2007), as well as shifts in age 
distribution towards older individuals following a pandemic, which we already 
observed in later epidemics of A(H1N1)pdm09 infection in Singapore (Win et al., 
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2011) and elsewhere (Mytton et al., 2012). If a durable humoral immune response to 
influenza in the elderly is unable to be maintained, then influenza vaccine 
development would need to focus on alternative strategies such as stimulation of T-
cell mediated immunity against influenza, as these may be better preserved than 
humoral immunity in the elderly (Greenbaum et al., 2009; Hsu et al., 2012; Kurupati 
et al., 2013). In addition, the findings also suggest that symptomatic infections may 
generate more robust immune responses than asymptomatic infections as indicated by 
the higher titres observed in the former by both HI and MN. However, the data was 
less clear on whether such higher titres would be sustained over time. 
Furthermore, the results also have important implications for the conduct of future 
sero-epidemiological studies, both using cross-sectional samples and cohort studies. 
Spacing serum samples more than 6 months apart may substantially underestimate 
infection rates by seroconversion using HI, depending on the timing of infections 
relative to the sample collection window, while about 90% of the initial 
seroconversions by MN could still be detected when using wider sampling intervals. 
If using a cross-sectional approach to estimate infection rates, we observed that, by 
samples B and C, only 25% and 14% had HI titres of ≥ 40, which is also used as a 
possible cut-off for indicating past infection. MN results reflected relatively higher 
prevalence of neutralizing antibodies, with 40% having titres ≥ 160 after 6 months 
and 37% after 1 year. More research is warranted to investigate the reasons for the 
differential rate of decline by HI and MN assays, and whether strain-specific antibody 
titres by HI or MN better predict protection against infections with the same influenza 
strain. Some studies comparing MN and HI to measure antibody responses to 
influenza A(H1N1) have demonstrated greater sensitivity of MN assays in the 
diagnosis of A(H1N1)pdm09, e.g. 83% versus 71% (Chan et al., 2011; Papenburg et 
al., 2011), and this may be related to differential antibody binding characteristics of 
the two assays. However, given that MN assays are much more labour intensive than 
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HI assays, large cohort studies involving testing for multiple subtypes and even 
strains within subtypes may remain dependent on HI assays, and restricting the 
spacing between samples to within 6 months would be an important design 
consideration for a cohort study relying solely on HI assays.  
There were several limitations to our study. Firstly, for logistical reasons, different 
but antigenically homologous A(H1N1)pdm09 strains were used for HI and MN 
assays. Moreover, HI results were based on assays performed in the same laboratory 
but in two separate batches. However, the sensitivity analysis indicated that the 
conclusions would remain essentially the same (unless titres in the second batch of HI 
assays were more than 2-fold higher than what we measured). Notably, while intra-
laboratory variation of HI titres of up to 2-fold in replicate assays is not uncommon, 
variation of more than 2-fold is rare (Wood et al., 2012). Another limitation was the 
relatively small number of older subjects, and the cohort was based on presumptive 
infections detected by seroconversion on HI assays. It must be remembered that even 
amongst RT-PCR-positive infections, about 20% do not seroconvert by HI, of which 
a small proportion do seroconvert by MN (Chen, Barr, et al., 2010). Logistical 
constraints prevented us from re-testing the entire set of about 2,000 samples from the 
initial epidemic by MN to identify these subjects. Secondly, follow-up of our subjects 
to obtain virological samples was not conducted, and while the two participants who 
were likely re-infected (as indicated by a ≥ 4-fold rise in titre after sample A) were 
excluded, the remaining 65 participants could still have included some whose 
subsequent titres were boosted by repeat exposure or infection. The decrease in titres 
might be even more dramatic if these individuals were excluded as well. Finally, 
while our study contributes some knowledge to the rate of decline in antibody titres 
following initial seroconversion to A(H1N1)pdm09, we are unable to address what 
might happen following repeated infections with the same strain, repeated infections 
with different strains of the same subtype, as well as whether the same findings apply 
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to influenza A(H3N2) or influenza B. Our cohort also comprised only healthy adults, 




Six months and one year after antibodies peaked following presumptive infection 
with A(H1N1)pdm09, only 25% and 14% of participants respectively had antibody 
titres against A(H1N1)pdm09 that would be considered protective (HI titre ≥ 40). The 
decline in antibody titres may explain susceptibility to re-infections, and recurrent 
epidemics following the initial epidemic of infections during the pandemic. It also 
suggests that influenza vaccination may have to be administered more frequently in 
the tropics where there is year-round circulation of influenza viruses. The rate of 
decline in elderly individuals may be even more rapid, and if our findings are 
confirmed, may necessitate alternative strategies of influenza vaccine development 





CHAPTER 3. T-CELL MEDIATED IMMUNITY 
3.1 Background of the study 
Humoral response has been established to be a key correlate of protection in influenza 
infection (Fox et al., 2015; Potter & Oxford, 1979), and the most commonly used 
vaccine formulations containing antigens derived from inactivated influenza viruses 
focus on boosting humoral response to circulating influenza strains (Cox, Brokstad, & 
Ogra, 2004). However, our analyses in chapter 2 reveals that influenza-specific 
antibody titres, at least for A(H1N1)pdm09, decrease rapidly from a seroprotective 
level (HI≥40) to non-seroprotective level over a period of six months to one year. 
This decrease in antibody titres is of particular concern for the older age group where 
the antibody decline is significantly faster than younger age groups. Therefore, 
establishing the existence of other mechanisms of protection against influenza 
infection may facilitate the development and uptake of alternative vaccine 
formulations, particularly for older individuals where the efficacy of the inactivated 
vaccine has been questioned (Sasaki et al., 2011). 
T-cell mediated immunity has been known to play an important role in viral clearance 
(Bender, Croghan, Zhang, & Small, 1992; Doherty, 1996). In recent years, it has been 
found that stronger pre-existing T-cell response predicts protection against seasonal 
or pandemic influenza disease (Altenburg et al., 2015; Sridhar et al., 2013). A recent 
study by Hayward et al further explored the cross-protective effect of T-cell mediated 
immunity against both seasonal and pandemic influenza infection; they found that 
presence of naturally occurring cross reactive T-cell mediated immunity protects 
against symptomatic influenza infection (Hayward et al., 2015). There is ongoing 
vaccine development against influenza that focuses on targeting more conserved T-
cell epitopes to generate immune response (Rimmelzwaan, Fouchier, & Osterhaus, 
2007) instead of the classical approach of inducing influenza-specific antibodies. 
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However, regulatory requirements for influenza vaccines continue to stipulate only 
induction of influenza specific antibodies (Chiu et al., 2013; Wood & Levandowski, 
2003). Our view is that this may be due to the lack of data clarifying how T-cell 
response might correlate with protection against infection, in spite of emerging 
evidence that T-cell response may offer cross protection against different influenza 
subtypes and is predictive of disease severity.  
In one of my previous studies (not part of this thesis), we observed that T-cell and 
antibody responses towards influenza A(H1N1)pdm09 virus infection were not well 
correlated, and vaccination against influenza A(H1N1)pdm09 was interestingly found 
to elicit a stronger T-cell mediated response in the elderly as compared to younger 
age groups (Hsu et al., 2012). That study hence suggests that it is possible to induce 
strong T-cell responses in the elderly provided the right antigens are used – in that 
case, a monovalent influenza A(H1N1)pdm09 vaccine. While, as pointed out earlier, 
there are now studies that suggest T-cell response predicts severity of influenza 
symptoms and is a correlate of protection against symptomatic influenza  (Altenburg 
et al., 2015; Hayward et al., 2015; Sridhar et al., 2013), several key questions remain 
unanswered. For one, all previous research (to our knowledge) was carried out in 
temperate regions, and there has been no research that we know of in tropical 
countries where influenza infections do not follow a clear seasonal cycle. Arguably, 
any vaccine-induced immune response has to be more durable for individuals in 
tropical regions where it is far more difficult to time influenza vaccination to precede 
influenza epidemics. It is hence important, not just to establish if T-cell mediated 
immunity protects against influenza, but if there is any evidence that the protection 
wanes with the passing of time which, as inferred from our previous study 
documenting a drop in antibody titres, might be the case for B-cell mediated 
protection. Secondly, in view of the need for establishing criterion for vaccine 
licensing, greater clarity is needed on how the profile of the T-cell response correlates 
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to protection, and the relationship of the protection conferred by T-cell response vis-
à-vis that conferred by antibody titres. For instance, does protection occur once some 
threshold T-cell response is achieved, or is there a more linear relationship, where 
there is incremental protection with increasing T-cell response? And is the T-cell 
response equally important in individuals with high and low antibody titres? These 
are issues which, in our opinion, were not adequately addressed in the prior studies 
just cited (Altenburg et al., 2015; Hayward et al., 2015; Sridhar et al., 2013).  
Therefore, the objectives of this study were to investigate, using a cohort study 
design, if baseline T-cell mediated immunity to Influenza 
A/Singapore/CDC204/2012(H3N2) strain measured at enrolment into the study was 
protective against subsequent influenza infection of the same and different subtypes, 
after accounting for potential confounding by antibody titres and demographic 
variables. We also characterize additional aspects of T-cell mediated protection, such 
as how the profile of T-cell response correlates with protection, if there was any 
evidence of the effect waning over time, whether it more strongly predicts protection 
against symptoms and against more severe symptoms as compared to serological 
infection, and if pre-existing T-cell response was correlated with the strength of the 
antibody response upon subsequent infection.  
 
3.2 Materials and Methods 
3.2.1 Study Design 
Participants in this study were from cohort of community dwelling individuals aged 6 
and above residing in Singapore. To maximize efficiency in deployment of 
manpower resources within the study, we performed rolling recruitment starting in 
February 2012, with the last participant enrolled in September 2013. Follow-ups 
started from September 2012 and with the last follow up sample was collected in 
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December 2013. Where possible, follow-ups were conducted approximately 6 months 
apart, with some allowances made to accommodate participants, and for the last few 
participants recruited, who had only about 100 days of follow-up. The cohort was 
sampled from those who previously participated in a multi-ethnic cohort (MEC) study 
under the Singapore Consortium of Cohort Studies (http://www.nus-
cme.org.sg/researcherParticipation.html) and had agreed to be re-contacted for future 
studies; their household members were invited to participate in the study during the 
home visits. Verbal consent was obtained from contacted participants of the previous 
MEC cohort studies through telephone prior to the home visit. Written consent was 
then obtained from participants on the first household visit; self-consent was obtained 
from individuals age 21 years old and above while parental/guardian’s consent in 
addition to assent from the participant for individuals below 21 years old. A baseline 
questionnaire was administered together with the collection of 20ml of venous blood 
(plain and heparin tubes) during the first visit. Follow up visits likewise included a 
follow up questionnaire and 20ml of venous blood until a total of up to four samples 
were collected from the same individual. The baseline questionnaire covered 
demographic details and prior influenza vaccination history, with information on 
additional influenza vaccination between study visits elicited in follow-up 
questionnaires. In addition, at enrolment, individuals were instructed to keep a diary 
of respiratory illness episodes encountered and voluntarily contact our staff if they 
had an episode with 2 or more of the following symptoms: fever, cough, sore throat 
and runny/blocked nose. Study staff then liaised with participants with such 
symptoms within 3 days from illness onset to collect flocked nasopharyngeal swabs 
to be stored in Universal Transport Medium vials and sent for investigation by RT-
PCR for influenza at the National Public Health Laboratory. Retrospective recall of 
respiratory illness episodes was also elicited during the follow-up visits to include 
information on acute respiratory illness (ARI) episodes where the participant had 
cough, sore throat or runny/blocked nose, and whether these episodes were 
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accompanied by self-reported fever, in which case the episode would also be 
considered a febrile respiratory illness (FRI).  
 
3.2.2 Laboratory Procedures 
3.2.2.1 Serum and PBMC isolation from whole blood  
Blood samples from participants were stored and transported at room temperature and 
then processed in a biosafety level 2 laboratory located in Department of 
Microbiology, National University of Singapore within 24 hours of collection. The 
plain and heparin tubes were centrifuged at 1500 rcf for 10 minutes at 20oC.  
Serum isolated from the plain tube was then aliquoted into cryovials and stored in -
80oC for future use. The plasma from the heparin tube was removed and discarded 
while the remaining components of the blood were re-suspended with equal volume 
of 1 x Phosphate Buffered Saline (PBS) then overlaid onto a sucrose medium known 
as Ficoll-Paque Plus solution of density 1.077g/ml (Amersham Biosciences, Uppsala, 
Sweden). This layered suspension was then centrifuged at 450 rcf for 30 minutes 
without deceleration to obtain layers of blood cells separated into its respective 
components. The buffy coat layer containing peripheral blood mono-nuclear cells 
(PBMCs), a thin cloudy layer that lies between plasma and Ficoll-Paque solution, was 
extracted then washed twice with 1X PBS. The washed PBMCs were resuspended in 
freezing media (Roswell Park Memorial Institute medium or RPMI-1640 + 20% fetal 
bovine serum (FBS) + 10% dimethyl sulfoxide (DMSO)) and aliquoted in 3.0X106 
cells/ml then slow-freezed to -80oC contained in a freezing container (Nalgene, USA) 





3.2.2.2 Influenza virus isolation and propagation 
The influenza PCR positive patient swabs were provided by Tan Tock Seng Hospital 
(TTSH). A/Singapore/CDC204/2012(H3N2), A/Singapore/GP2651/2009(H1N1), 
B/Singapore/CDC45/2012(Yamagata lineage-like) and 
B/Singapore/CDC29/2012(Victoria lineage-like) were isolated from the swab, filtered 
and inoculated in MDCK cell line. Confluent MDCK cell line in 24-wells plates were 
pre-treated with TPCK-Trypsin to allow virus penetrance by lowering the tension of 
cells. The plates were sealed and incubated in 35oC with 5% CO2 incubator. 
Cytopathic effects (CPE) were observed over the next 72 hours using an inverted 
microscope. Once CPEs had been observed to be approximately 60%, 100µl of 
supernatant fluid were transferred into each of the new wells in the 24-well plates 
consisting of confluent MDCK cell lines to scale up the virus quantities to obtain 
sufficient virus titres. Virus was then harvested and stored at -80oC for future use in 
assay.  
 
3.2.2.3 IFN-γ ELISPOT Assay  
ELISPOT assays were used to measure cellular immunity response by quantifying 
IFN-γ production. Triplicate assays were performed for each sample using 
multiscreen 96-well plates (Millipore, Billerica, MA, USA) which were coated 
overnight at 4oC with 5 mg/ml of anti-human IFN-γ capture antibody (Mabtech, 
Nacka Strand, Sweden). Plates were blocked with AIM-V medium (Invitrogen, 
Carlsbad, CA, USA) supplemented with 10% FBS for 2 hours at room temperature. 
Cryopreserved PBMCs were thawed, washed, counted and added to the plates in 
triplicate at 105 PBMCs per well in AIM-V medium supplemented with 2% human 
serum (HS).  The cells were then incubated at 37oC for 5 hours before concanavalin A 
(Con A) (Sigma-Aldrich, St. Louis, MO, USA) was added to the positive control 
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wells at 5 mg/ml to ensure the viability of the PBMCs tested. Filtered 
A/Singapore/CDC204/2012(H3N2) virus was added to the test wells at a multiplicity 
of infection (MOI) of three before further incubation at 37oC for 16 hours. Plain 
medium with PBMCs served as negative control. Plates were washed and incubated 
for 2 hours with 2 mg/ml of biotinylated anti-IFN-γ secondary detection antibody 
(BD Biosciences, San Jose, CA, USA), followed by 1 hour incubation with 
streptavidin–horseradish peroxidase (HRP) enzyme and substrate (BD Biosciences) at 
room temperature. 3-Amino-9-ethylcarbazole (AEC) chromogen in substrate solution 
(BD Biosciences) was added to each well for spot development. The plates were then 
read and counted by an automated ELISPOT reader (Cellular Technology, Shaker 
Heights, OH, USA). One spot formed in a well reflects one IFN-γ producing cell, and 
the size of the spot is proportional to the amount of IFN-γ produced (Karlsson et al., 
2003). Mean spot-forming units (SFU) of the triplicates were calculated after 
subtracting the number of spots in the negative well from the test well.   
 
3.2.2.4 Haemaglutination inhibition (HI) assay 
Serum samples were pre-treated with RDE (Deka Seiken Co Ltd, Tokyo, Japan), 1:4 
(vol/vol), at 37°C for 16 hours, before enzyme inactivation by the addition of an 
equal volume of 1.6% trisodium citrate (Ajax Chemicals, Melbourne, Australia) and 
incubation at 56°C for 30 minutes. 
HI assay was performed according to standard protocols at the World Health 
Organization Collaborating Centre for Reference and Research on Influenza in 
Melbourne, Australia (Kendal et al., 1982). MDCK-grown 
A/Singapore/CDC204/2012(H3N2), A/Perth/16/2009(H3N2), 
A/Victoria/361/2011(H3N2), A/Singapore/GP2651/2009(H1N1), 
B/Singapore/CDC45/2012(B, Yamagata lineage-like) and 
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B/Singapore/CDC29/2012(B, Victoria lineage-like) viruses were diluted to 4 
hemagglutination units before the assay was performed. 25 μL of the diluted virus 
was incubated at room temperature with an equal volume of RDE-treated serum. 
Serum samples were titrated in 2-fold dilutions in phosphate-buffered saline from 
1:10 to 1:1280. Following 1 hour of incubation, 25 μL of 1% (vol/vol) turkey red 
blood cells (used for H1N1 and influenza B viruses) or guinea pig RBCs (used for 
H3N2 viruses) was added to each well. Hemagglutination inhibition was read after 30 
minutes. Titres were expressed as the reciprocal of the highest dilution of serum 
where hemagglutination was prevented.  
 
3.2.2.5 Real-time reverse transcription-PCR  
The nasopharyngeal swab obtained from the participants who reported with 
influenza-like symptoms were send to National Public Health Laboratory for RT-
PCR confirmation of influenza. Each sample RNA extract is tested by separate primer 
set. Negative (no template control, nuclease free water) and positive (positive 
template control RNA) controls for all primers were included in each run. A 
secondary negative control (human specimen control) is also included to validate the 
nucleic extraction procedure and reagent integrity. Each swab sample is added with a 
cocktail of reagent mixture in a 96-well reaction plate. The specimen-reagent mixture 
was mixed well before running the samples with programmed thermocycler. The viral 
genes were amplified by RT-PCT to a threshold and the cycles needed for 





3.2.3 Statistical Analysis 
HI titres below 10 were assigned a value of 5 while HI titres of 1280 or higher were 
assigned a titre of 1280. The assigned values were then log-transformed in estimating 
geometric mean titres (GMTs) and other analyses since the distribution of HI titres is 
right skewed. For ELISPOT response, the positivity criteria suggested by the kit were 
not followed as exploratory analysis suggested that the raw values were more 
informative. Because the distribution of ELISPOT responses was also right skewed, 
log-transformation was also used to normalise the distribution. After subtracting the 
negative background away from the test wells, and obtaining the mean for the 
triplicate assays for each sample, values smaller or equal to zero were assigned a 
value of 0.167 (half of the lowest possible positive value of 1 SFU amongst the 3 
assays for that sample); these values were then log-transformed. 
To assess the effect of antibody titres and ELISPOT responses on risk of infection 
and symptomatic infection with each influenza subtype, we defined three outcomes of 
interest as follows. Firstly, we defined seroconversion (SC) as a 4-fold or greater 
increase in antibody titres between any two consecutive samples for any of the strains 
tested for each of the subtypes i.e. 3 strains for influenza A H3N2 
(A/Singapore/CDC204/2012(H3N2), A/Perth/16/2009(H3N2) and 
A/Victoria/361/2011(H3N2)), only 1 strain for influenza A H1N1 
(A/Singapore/GP2651/2009(H1N1)), and 2 strains for influenza B 
(B/Singapore/CDC45/2012 (B, Yamagata lineage-like) and 
B/Singapore/CDC29/2012(B, Victoria lineage-like)). The second outcome was a 
subset of the first, being defined as seroconversion accompanied by an acute 
respiratory illness episode (SC-ARI) as reported by the participant within the interval 
between the two consecutive samples (either informed to the study team upon onset 
of symptoms or retrospectively recalled at the follow-up visit). Finally, the third 
outcome was likewise a subset of the second, being defined as seroconversion 
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accompanied by an acute febrile respiratory illness episode (SC-FRI). In instances 
where seroconversion occurred, we also established the greatest titre change amongst 
the strains assessed for each subtype for correlation with the baseline ELISPOT.  
Depending on the analysis, the unit of analysis was either the participant, where each 
participant contributes only 1 observation, or the participant-interval-subtype, where 
each participant contributes up to a maximum of 9 observations (3 subtypes observed 
over 3 intervals). The participant was the unit of analysis in multivariate linear 
regression exploring associations between demographic characteristics and prior 
vaccination with baseline HI titres to the six influenza strains and ELISPOT response 
to A/Singapore/CDC204/2012(H3N2) with, as well as in graphical plots of the 
proportions of individuals who ever had each of the three outcomes of interest (SC, 
ARI and FRI) over the study period by baseline HI titres and ELISPOT response; 
because ELISPOT response was a continuous variable, a Loess smoothing technique 
was used with the latter to smooth the curve contributed by the numerous values for 
ELISPOT responses. The participant-interval-subtype was the unit of analysis in a 
combined analysis of all data observed during the study period; this simultaneously 
allowed us to account for the different number of follow-up intervals between 
participants, combine information from the different subtypes assessed, and account 
for the potential effect of changing subtype specific HI titres for each participant at 
the start of each interval. To do this, we used a multi-level multivariate logistic 
regression model with up to 4 levels, where outcomes were assessed for each of the 
influenza subtypes, nested within intervals corresponding to pairs of serological 
samples assessed for all 3 subtypes, nested within the participant contributing the 
samples which bookmark up to 3 intervals per participant, who in turn are nested 
within households from which one or more participants were recruited. We also 
performed a stratified analysis restricted to just the H3N2 subtype (i.e. 3 levels, with 
the smallest level being the participant-interval), and the A(H1N1)pdm09 and B 
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subtypes combined (with the original 4 levels). Grouping observations from 
A(H1N1)pdm09 and B subtypes allowed us to study the effect of baseline T-cell 
mediated immunity (which was assessed only for a H3N2 strain) on protection 
against heterotypic influenza infections in spite of the smaller number of 
seroconversion events obtained for each of these two subtypes. 
The multilevel multivariate model included variables from four different categories: 
a) demographic characteristics, b) vaccination history, c) subtype specific HI 
antibody titres at baseline and at the start of each interval and d) log of ELISPOT 
response, and e) variables related to the timing of sample collection. For the H3N2 
and B subtypes, we used the antibody titres to the one strain which on exploratory 
analysis was most predictive of protection, which was A/Victoria/361/2011(H3N2) 
and B/Singapore/CDC45/2012 (B, Yamagata lineage-like) respectively. The variables 
related to the timing of sample collection included interval duration, which is the time 
between two corresponding sampling time-points, and adjustment allows fair 
comparison, particularly with participant intervals towards the end of the study where 
the interval between follow-ups were shorter, or those who skipped follow-up 
samples where the interval would be much longer; it also includes time from 
enrolment to the midpoints between two corresponding sampling time-points, which 
was used mainly to assess if there was any evidence that T-cell mediated immunity 
measured at baseline was less predictive of protection against influenza in the latter 
part of the study. This was done by including an interaction term with time from 
enrolment to midpoint dichotomised at 277 days to give approximately equal 
numbers of observations on both sides of the cut-off. Other interactions with the 
effect of ELISPOT response that were similarly explored were for HI titres at the start 
of each interval, divided into (<20 or ≥20) to account for the interaction effect of 
ELISPOT response and HI titres, and age dichotomized at <55 and ≥55 years 
(corresponding to the findings from the study in Chapter 2). Strata-specific effects of 
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ELISPOT response is presented in all instances where there was evidence of 
interaction (at p<0.10) and other selected analyses for comparison.  
Observations from individuals reporting vaccination within the study period were 
excluded from analysis of outcomes related to seroconversion, since vaccination 
causes seroconversion, making it impossible to assess if infection occurred using 
serology. In addition, because it is possible that any infection during the study period 
could modify the ELISPOT response, we also performed a sensitivity analysis for the 
multilevel multivariate model where subsequent participant-intervals were excluded 
from the analysis if an infection event (regardless of subtype) occurred for that 
participant within a previous study interval. 
All statistical analyses were performed using STATA 11.0 (StataCorp, College 
Station, TX, USA). 
 
3.2.4 Ethics Review  







A total of 507 participants were recruited. Due to the rolling recruitment and 
participants dropping out from the study, not every participant contributed the 
maximum four samples. Demographic characteristics, vaccination history and reports 
of ARI and FRI by participant and participant-intervals are shown in Table 3.1, with 
participant-intervals designated by the consecutive samples available for analysis for 
each participant, including a category for those with ‘skipped follow-ups’ (i.e. 
instances where participants were not followed up at the scheduled sampling time-
points but skipped one or even two follow ups, in which case the next available 
sample was taken). Most observations kept to the intended schedule with only 68 
(6.39%) participant-intervals derived from skipped follow-up samples. The dropout 
rate was highest in the age 6 to 19 years old group with the result that the contribution 
from this age group decreased from 18.5% in the first interval to 15.8% in the last 
interval. The largest proportion of participants was from the age group 40 to 59 years 
old (46.0%). 19.9% of participants reported having ever had influenza vaccine, but 
only 6.3% had vaccination within 1 year of enrolment. 6.9% of participants reported 
influenza vaccination during the study, and these individuals were excluded from 
analysis of serological infection. The frequencies of ARI and FRI shown in the table 
were derived from the questionnaire and they were self-reported by the participant. 
The total numbers for ARI and FRI for participant is less than the sum of all 
participant-intervals as some participants had reported ARI/FRI for more than one 
interval or had several episodes of ARI/FRI in one interval. Not shown in Table 3.1, 
there were 10 participants returned to be PCR positive for influenza, and they were 
followed up with a closer time interval schedule. The number of ARI and FRI were 




Table 3.1. Table of participant characteristics and follow-up events, for all 
participants at enrolment, and for participant intervals where follow-up samples 




By participant-interval (n=1064) 




1st to 2nd 
follow-up 
(n=336) 







6-19 97 (19.1) 80 (18.5) 55 (16.4) 37 (15.8) 10 (14.7) 
20-39 129 (25.4) 103 (24.2) 80 (23.8) 54 (23.1) 21 (30.9) 
40-59 233 (46.0) 204 (47.9) 165 (49.1) 121 (51.7) 33 (48.5) 
60 and above 48 (9.5) 39 (9.2) 36 (10.7) 22 (9.4) 4 (5.9) 
Gender 
Male 211 (41.6) 182 (42.7) 147 (43.8) 99 (42.3) 27 (39.7) 
Female 296 (58.4) 244 (57.3) 189 (56.3) 135 (57.7) 41 (60.3) 
Vaccination before study 
No 
vaccination 




69 (13.6) 55 (12.9) 42 (12.5) 25 (10.7) 12 (17.7) 
Vaccination 
within 1 year 
before study 
32 (6.3) 29 (6.8) 21 (6.3) 12 (5.1) 4 (5.9) 
Vaccination during study‡ 
No 
vaccination 
472 (93.1) 404 (94.8) 327 (97.3) 230 (98.3) 66 (97.1) 
Has 
vaccination 
35 (6.9) 22 (5.2) 9 (2.7) 4 (1.7) 2 (2.9) 
Acute Respiratory Illness (ARI)‡ 
 No ARI 291 (57.4) 302 (70.9) 257 (76.5) 170 (72.7) 43 (63.2) 
Has ARI 216 (42.6) 124 (29.1) 79 (23.5) 64 (27.4) 25 (36.8) 
Febrile Respiratory Illness (FRI) ‡ 
No FRI 404 (79.7) 370 (86.9) 302 (89.9) 214 (91.5) 59 (86.8) 
Has FRI 103 (20.3) 56 (13.2) 34 (10.1) 20 (8.6) 9 (13.2) 
†instances where participants were not followed up at the scheduled sampling time-
points but skipped one or even two follow ups, in which case the next available 
sample was taken; possible combinations include Enrolment to 2nd follow-up sample, 
Enrolment to 3rd follow-up sample and 1st follow-up to 3rd follow-up sample. 
‡total numbers for participants is less than the sum for all participant-intervals as 
some participants had vaccination/ARI/FRI in more than 1 study interval 
 
 
Figure 3.1A illustrates the rolling recruitment with the staggered start and end dates 
for different participants. The green lines represent the time period contributed by 
each participant during the study period, with each shade of green representing the 
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interval between two consecutive sampling time points, and shows that the periods 
arbitrarily designated as B and C had far more individuals under observation than 
periods A and D.  
The epidemic waves of H3N2, A(H1N1)pdm09 and influenza B during the study 
period were reconstructed based on the weekly influenza-like illness samples from 
sentinel primary care clinics positive for the respective subtype as obtained from 
statistics published by Ministry of Health (MOH) 
(https://www.moh.gov.sg/content/moh_web/home/statistics/infectiousDiseasesStatisti
cs/weekly_infectiousdiseasesbulletin.html?year=2013). There were four clear waves 
of H3N2 epidemic activity (Figure 3.1B), each falling within one of our designated 
periods, and one clear wave of A(H1N1)pdm09 epidemic activity (Figure 3.1C) in 
period B. Epidemics of influenza B are less distinct, but there was clearly substantial 
epidemic activity before the study (Figure 3.1D) for which the seroconversion events 
would not be captured in our study. Given both Yamagata and Victoria-lineages of 
the influenza B have known to co-circulate for the past few years with different strain 
dominating in different countries, the two strains were grouped together as ‘influenza 
B subtype’ for subsequent analyses in this study. While there were sparse 
observations of SC-ARI and SC-FRI during the study period, these appeared to 
coincide fairly well with surges of epidemic activity to the corresponding subtype, 
suggesting that they did reflect episodes of influenza infection in spite of the lack of 
virological confirmation in the majority of these episodes. Cumulatively, 82, 23 and 
30 individuals seroconverted to influenza A H3N2, H1N1pdm09 and B respectively 
during the study period (Figures 3.1B-D). For H3N2, the greatest number of 
seroconversions (74) was to A/Perth/16/2009(H3N2), followed by 60 and 50 




























Figure 3.1. Distribution of influenza waves during the study period. Each line represents the time contributed by each participant in the study 
(3.1A). The study period is arbitrarily divided into periods A and D to keep the epidemic waves for the various subtypes within a distinct period. 
In Figures 3.1B-D, orange and red bars represent seroconversions accompanied by acute respiratory illness (SC-ARI) and febrile respiratory 
illness episodes (FRI) respectively, while grey areas denote epidemic activity from Ministry of Health (MOH) surveillance data for the respective 
subtype. Figures 3.1E-J show the HI titre distributions of all six influenza strains in the study period; the bars represent the proportion of 
participants having the particular geometric titres from HI assay (orange bar represents the highest geometric titre while blue bar represents the 
lowest geometric titre); the black points and lines represent the geometric mean HI titres with 95% confidence interval. 


















































Epidemiological week and calendar dates




B. Cumulative influenza A H3N2 seroconversions and ARI/FRI vs H3N2 surveillance data

















































Epidemiological week and calendar dates
Cumulative, H1N1pdm09
C. Cumulative influenza A pdmH1 seroconversions and ARI/FRI vs pdmH1 surveillance data









































Epidemiological week and calendar dates
Cumulative, all B strains
Cumulative B/Singapore/CDC45/2012 (Yamagata lineage)
Cumulative B/Singapore/CDC29/2012 (Victoria lineage)
D. Cumulative influenza B seroconversions and ARI/FRI vs B surveillance data
H3N2 (MOH surveillance)
SC-ARI for H3N2 (cohort)
SC-FRI for H3N2 (cohort)
H1N1pdm09 (MOH surveillance)
SC-ARI for H N1pdm09 (cohort)
SC-FRI for H1N1pdm09 (cohort)
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SC-FRI for B (cohort)
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Calendar dates in 2012 and 2013
A. Participant enrollment and follow-up dates













































































































































































































Using the designated periods A to D, which were arbitrarily chosen to keep the epidemic 
waves for the various subtypes within a distinct period, we constructed Figures 3.1E-J 
which give the profile of the population-level immunity to all six influenza strains 
assayed throughout the study period. We observed an increasing trend for the proportions 
with higher titres against A/Perth/16/2009(H3N2) which was significant on chi-squared 
test for trend (p=0.019), but there was a decreasing trend for all the other five influenza 
strains tested, which was statistically significant for A/Victoria/361/2011(H3N2) 
(p=0.006) and B/Singapore/CDC45/2012 (B, Yamagata lineage-like) (p<0.001). 
Figure 3.2 gives the coefficients for the associations between demographic characteristics 
and vaccination history with the baseline HI titres to any of the six strains tested and the 
baseline ELISPOT response on multivariate linear regression. Increasing age was 
associated with lower HI titres to all influenza strains, and significantly so for all three 
H3N2 strains, A/Singapore/GP2651/2009(H1N1) and B/Singapore/CDC45/2012 (B, 
Yamagata lineage-like); there was, however, no evidence of association between older 
age and ELISPOT response to A/Singapore/CDC204/2012(H3N2). Receipt of influenza 
vaccine within one year before the study was associated with significantly higher HI 
titres for A/Victoria/361/2011(H3N2), A/Singapore/GP2651/2009(H1N1), and both 
influenza B subtype strains but not with ELISPOT response. Females had a significantly 
lower ELISPOT response (Coefficient = -0.36, 95% CI = -0.68, -0.05, p-value = 0.023), 




     
Figure 3.2. Comparison of HI titres and ELISPOT response in different demographic variables. Figure 3.2 compares the coefficients of 
baseline HI titre from each influenza strain and ELISPOT response of A/Singapore/CDC204/2012(H3N2) obtained from multivariate linear 















































Figure 3.3. Association between HI titres (baseline and most recent HI titres) with 
percentage outcomes: 1) Seroconversion (SC, orange bars), 2) Seroconversion with 
ARI (SC-ARI, green bars), or 3) Seroconversion with FRI (SC-FRI, blue bars). Error 
bars denote 95% confidence intervals. Left panels are for titres at baseline, where the 
participant is the unit of analysis, while right panels are for titres at the start of each 


















































































































































































































































































































































































































































Figure 3.3 graphically assesses the association between HI titres at baseline and at the 
start of each interval to all six strains assayed and the three different outcomes: 1) 
seroconversions (SC), 2) seroconversion accompanied by ARI (SC-ARI), and 3) 
seroconversion accompanied by FRI (SC-FRI). The baseline HI titres shown on the left 
panel was analysed with the participant level unit of analysis (n=432) while the most 
recent HI titres shown on the right panel was analysed with participant-interval unit of 
analysis (n=978). There are clear negative associations between HI titres and 
seroconversion, with higher HI titres being more protective against influenza 
seroconversion (SC) as well as symptomatic presentations of infections (ARI and FRI). 
While not all that apparent from the figures, exploratory regresssion analyses suggested 
that HI titres at the start of the interval (Figure 3.3B, D, F, H, J, L) show a stronger linear 
relation with protection than baseline HI titres (Figure 3.3A, C, E, G, I, K). With the 
exception of A/Singapore/GP2651/2009(H1N1) (Figure 3.3G and H), for most of the 
strains, there is no obvious threshold effect where those with titres above the threshold 
are protected while those below are at equally increased risk. The relationship is similar 
for ARI and FRI for H3N2 (Figures 3.3A to F) and to some extent for influenza B. 
However, it must be noted that ARI is a subset of seroconversion and FRI is a subset of 
ARI, and therefore the number of observations for these outcomes are very small, in 





The association between T-cell mediated response and outcomes were also analysed 
(Figure 3.4). Graphs of seroconversion (SC), seroconversion with ARI (SC-ARI) and 
seroconversion with FRI (SC-FRI, Figures 3.4A-C respectively) were plotted for each 
subtype at different log of ELISPOT (SFU) cut-off points as indicated by the coloured 
bars. Lowess curve for each subtype was also plotted in each figure to emphasize the 
trend, where we demonstrate a linear decreasing trend in the percentage with the various 
outcomes with increasing ELISPOT responses. This suggests there is no clear threshold 
effect, but that increasing protection towards influenza infection (both symptomatic and 
asymptomatic) is conferred by increasing T-cell mediated immunity, and that there is 
evidence for both homotypic (H3N2) and heterotypic (A(H1N1)pdm09 and B) protection 




Figure 3.4. Association between percentage outcomes (A. Seroconversion; B. 
Seroconversion with ARI; or C. Seroconversion with FRI) with baseline HI titre and 
most recent HI titre of all three influenza subtypes tested. Decreasing percentage of 
























































































Figure 3.5 shows the result from our multi-level multivariate logistic regression analyses. 
Figure 3.5A shows that a longer time interval between two consecutive sampling time-
points significantly increases the chance of an individual being infected by influenza, 
while time from enrolment may be associated with a significantly decreased risk of 
seroconversion with FRI (and particularly so for H3N2); it may hence be necessary to 
adjust for interval duration and time from enrolment when assessing the association 
between other variables and the respective outcomes. There was also a negative 
association of SC-FRI as outcome with age that was borderline significant (p=0.062) and 
significant on the stratified analysis for the H1N1pdm09 and B combined (p=0.046), but 
gender was not a risk factor for symptomatic or asymptomatic influenza infection. No 
significant associations were observed between symptomatic or asymptomatic 
seroconversion with vaccination history (Figure 3.5B). In Figure 3.5C, it is observed that 
HI titres at baseline do not confer protection against influenza infection, and it elevates 
risk after adjusting for titre at the start of the interval. On the other hand, Hi titre at the 
start of the interval confers significant protection against symptomatic (with and without 
fever) and asymptomatic influenza infection, a relationship which is consistent in the 
stratified analysis for both H3N2 and H1N1pdm09 and B combined. Figure 3.5D shows 
the effect the ELISPOT response (on a log scale) adjusted for potential confounding by 
all other variables in Figure 3.5. T-cell mediated immunity is found to be protective to 
symptomatic and asymptomatic influenza infections of all subtypes; there is a trend 
towards a stronger protective effect with symptomatic forms of infection as evidenced by 
the smaller odds ratios, although the p-value for SC-FRI is only borderline significant 
(p=0.076). HI titres at the start of the interval significantly modified the effect of 
ELISPOT response for SC-ARI and SC-FRI outcomes; we see that ELISPOT response is 
significantly protective in those with HI titres <20 but not those with HI titres ≥20, and 
this relationship also holds in the stratified analysis for H3N2 but not H1N1pdm09 and B 
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combined. In the case of time from enrolment, which significantly modified the effect of 
ELISPOT for seroconversion (SC) as an outcome, there is overall a significantly reduced 
risk of infection for intervals where the midpoints were <277days from enrolment, which 
also was true for both H3N2 and H1N1pdm09 and B combined, but no significant effect 
observed for later intervals (≥277days from enrolment).  
Sensitivity analysis was performed excluding participant-intervals after an infection event 
occurred. The results showed stronger associations, with more significant p-values 
observed between log-transformed ELISPOT SFU and the variables analysed in the 
multi-level multivariate logistic regression model for all subtypes combined. However, 
due to the reduced number of observations available, the model had problems converging 





Figure 3.5. Multi-level multivariate analyses adjusted for A) demographic 
characteristics, interval duration and time from enrolment, B) vaccination history, 
C) HI antibody titres and D) log-transformed ELISPOT SFU with stratification by 
HI titres at the start of the interval and time from enrolment. Note that some of the 
upper and lower limits of the confidence intervals are truncated. Bars give the results for 
all subtypes combined, with the grey zone indicating the point estimates for odds ratios, 
and the purple, orange and red zones denoting 95% confidence intervals  for non-
significant results, and results with p<0.10 and p<0.05 respectively. Diamond and 
triangle symbols denote stratified results for H3N2, and combined outcomes for 
H1N1pdm09 and B respectively. Closed symbols are results at p<0.10, while symbols 
with a black border are those significant at p<0.05. Associations could not determine for 
some variables due to zero-cells in some of the stratified analyses.  
†Time from enrolment is dichotomised for the analysis of interaction with ELISPOT at 
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To further clarify the relationship between pre-existing T-cell and antibody immunity, 
Figure 3.6 plots the geometric mean of the baseline ELISPOT response measured in SFU 
by the fold-change in HI titres. It is observed that there is a decreasing baseline ELISPOT 
response in those with increasing fold change in HI titres for all subtypes combined, 




Figure 3.6. Association between ELISPOT response with fold change in HI titres. 
Bars give the results for all subtypes combined, with the grey zone indicating the point 
estimates for the geometric means of ELISPOT, and the purple zones denoting 95% 
confidence intervals. Diamond, circle and triangle symbols denote stratified results for 










































The primary objective of this study was to investigate whether baseline T-cell mediated 
immunity to A/Singapore/CDC204/2012(H3N2) confers protection to subsequent 
influenza infections (homotypic and heterotypic) based on a cohort of healthy 
individuals, and to further characterise the nature of the protection, in particular if 
protection differed by the presenting syndrome, whether there was any interaction with 
antibody mediated protection, and the effect of time from initial measurement of the T-
cell response. We found that pre-existing T-cell response conferred protection, that there 
was no clear threshold effect but that the protection increased in a near linear fashion 
with increasing values of the log of T-cell response; we also found on multilevel logistic 
regression that the effect remained significant upon adjusting for possible confounding 
factors such as age, gender, antibody titres and time from enrolment. The cohort in this 
study consists of healthy individuals from the Singapore community and is likely 
generalizable to other healthy populations. Unlike in temperate countries, influenza 
infections in tropical countries do not follow seasonal cycle, and the tropical setting 
coupled with the rolling recruitment also allowed us to explore the effect of time on 
baseline titres and ELISPOT response, since the risk of infection was not concentrated 
into seasonal epidemics but distributed across the study period of close to two years.  
In comparison with another recent study which demonstrated protection by T-cell 
mediated immunity, instead of the method of stimulating PBMCs with peptide pools in 
ELISPOT assay (Hayward et al., 2015), the whole influenza virus was used in this study 
to stimulate PBMCs. While using peptide pools does have its advantages (in being able to 
pinpoint the response from the exact epitopes), but one advantage of using the whole 
virus is that it allows the actual influenza infection in vivo to be mimicked, where viruses 
were able to interact directly with immune cells also present in the PBMC samples. We 
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believe using such a method for deriving correlates of protection has more adaptability 
for future assessment of vaccine updates for the purposes of vaccine licensing, much in 
the way that current HI and MN assays are performed with new circulating strains which 
arise in the event of antigenic drift. In our case, the A/Singapore/CDC204/2012(H3N2) 
was chosen because it was antigenically similar to the A/Victoria/361/2011(H3N2)-like 
which we anticipated would circulate during our study period. Related to this, it must be 
noted that the study spanned the transition period where A/Perth/16/2009(H3N2)-like 
were being replaced by A/Victoria/361/2011(H3N2)-like strains (Fantoni et al., 2014; 
Liao, Lin, & Lin, 2013), and the recommended influenza vaccine formulation also 
changed from A/Perth/16/2009(H3N2) to A/Victoria/361/2011(H3N2) ("Recommended 
composition of influenza vaccines for use in the 2012 southern hemisphere influenza 
season," 2011; "Recommended composition of influenza virus vaccines for use in the 
2013 southern hemisphere influenza season," 2012) around the time of our study period. 
This necessitated the use of these two vaccine strains in addition to the 
A/Singapore/CDC204/2012(H3N2) which was isolated during our study period and used 
as a proxy for A/Victoria/361/2011(H3N2) before the latter became available to our study 
team. Basic Local Alignment Search Tool (BLAST) analyses to compare the sequences 
of the hemagglutinin and neuraminidase of the two H3N2 strains revealed nucleotide and 
amino acid identities of 96%, and subsequent HI assays found that the titres measured to 
the two strains were the most closely correlated as compared to the other strains analysed 
(r=0.85, p<0.001), thus confirming their strong homology.  
One finding that was not in line with the main objective of our study, but is important to 
note and explain is the significant decreasing trend observed in population-level 
immunity towards the A/Victoria/361/2011(H3N2)-like strains and paradoxically the 
significant increasing trend in population-level immunity towards 
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A/Perth/16/2009(H3N2)-like strains during the study period, in spite of the fact that the 
former was the dominant circulating strain during the study period. We suggest that the 
significant decreasing trend for the A/Victoria/361/2011(H3N2)-like strain (and also the 
B/Singapore/CDC29/2012(Victoria lineage-like)) reflects the phenomenon highlighted in 
Chapter 2, of rapid waning of antibody titres (as assayed by HI). As for the increase in 
titres to the A/Perth/16/2009(H3N2)-like strains, we suggest this could be explained by 
the ‘back-boost’ mechanism proposed by Fonville et al where, depending on the 
similarity between the strains, infection with the new strain may lead the immune system 
to recall antibodies from recent infections to an even greater extent than it generates 
antibodies to the new strain (Fonville et al., 2014). In this case, we suggest that, while 
there were antigenic differences between the A/Victoria/361/2011(H3N2)-like and 
A/Perth/16/2009(H3N2)-like strains, there was sufficient similarity that “antigenic 
trapping” would lead to reduced stimulation of specific antibodies to the new strain but 
boosting of immunity to the previous circulating strain.  
However, the most critical findings from this study relate to the evidence presented that 
T-cell mediated immunity confers significant protection against symptomatic (without 
fever) and asymptomatic influenza infection; we were also able to demonstrate 
significant homotypic protection (for H3N2), with an increasing level of protection to 
symptomatic presentations of influenza infection (i.e. protection to SC-FRI > SC-ARI > 
SC), and although the protection observed against heterotypic infection was non-
significant when analysing all participant-intervals, the stratified analysis suggests that T-
cell protection is active for observations where the midpoint is less than 277 days from 
the time from enrolment. Finally we also demonstrated that the effect of T-cell mediated 
immunity is active mainly in observations where HI titres are low at the start of the 
interval but has no effect at HI titres ≥20. These findings have thus far had support in 
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studies from animal models. For instance, our finding that the effect of T-cell mediated 
immunity declines over time was documented in a mouse model, where Humphrey et al 
demonstrated loss of protective CD8+ T-cell immunity 6 months post-infection 
(Humphreys et al., 2012). We now verify that the same phenomenon occurs in humans, 
with important implications for future influenza vaccination strategies that aim to 
stimulate T-cell mediated immunity against influenza. Our finding on the relation 
between antibody titres and T-cell mediated immunity is important because it challenges 
the belief that T-cell mediated immunity is independent of antibody immunity. Our 
findings also concur with a review by La Gruta & Turner, which summarized evidence, 
largely from animal model studies, showing that T-cell mediated immunity mainly plays 
an important protective role when antibody immunity is ineffective (La Gruta & Turner, 
2014). This suggests an important alternative vaccination strategy in groups which either 
fail to mount an effective antibody response, or where the antibody response may be 
more transient, such as the elderly (as demonstrated in Chapter 2). Finally, our findings 
also challenge the classical thinking that, because CD8+ T-cells mediates viral clearance 
and CD4+ T-cells help in antibody and other immune responses, T-cell immunity can 
only protect against symptomatic but not serological infection. However, there is 
evidence, again from animal studies (Budimir et al., 2013; Guo, Santiago, Lambert, 
Takimoto, & Topham, 2011), that T-cell mediated protection against serological infection 
occurs. Our finding on the association of the strength of the T-cell response and the 
change in antibody titres suggests to us that there are different intensities of influenza 
infection ranging from asymptomatic to mildly symptomatic to infection with more 
systemic symptoms like fever; rapid clearance of viral antigens following a limited 
(possibly localised) infection may result both in less symptoms and a weaker antibody 
response that may not result in the traditionally accepted 4-fold or greater increase in 
titres. This would explain our observations on the role of higher T-cell response in 
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protecting against serological infection, as well as the more muted antibody change upon 
infection in those with higher T-cell response. The correlation between lesser symptoms 
and a weaker antibody response is also supported by the findings from our study in 
Chapter 2, as well as data from one of our unpublished studies where we observed several 
asymptomatic influenza PCR positive infections which both did not have symptoms and 
also did not mount the classical 4-fold or greater increase in titres on follow-up 
serological samples. 
Finally, other findings of note include the lack of evidence for protection from prior 
vaccination. Vaccination status was found though to have a significant and a non-
significant positive association with HI titres and ELISPOT responses respectively 
(Figure 3.2). This apparent contradiction between association with higher immune 
markers but lack of protective efficacy could possibly be explained in the light of 
findings from Chapter 2 where we showed how rapidly antibody titres decrease, and also 
the possibility that many of those vaccinated prior to our study period would have 
received a vaccine formulation without the A/Victoria/361/2011(H3N2)-like strain which 
was the main influenza virus circulating during our study period. 
There are some limitations to our study. Firstly, response to other influenza subtypes 
(H1N1 and B), as well as differentiation into CD4+ and CD8+ T-cell populations were 
not analysed by flow cytometry due to the limited quantity of blood sample and PBMCs 
obtained from each participant. Further studies may be helpful for distinguishing the two 
T-cell subsets, and for identifying the relevant T-cell epitopes which may in turn be 
useful for future vaccine development based on T-cell epitopes. T-cell epitope prediction 
techniques may also be employed to determine the T-cell epitopes responsible for the 
response. We also did not include results from virus neutralisation assays in this study, 
due to resource constraints in organising such assays for 6 strains in more than 1,000 
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samples. Also, there was a lack of virological confirmation of influenza infection for the 
majority of our respiratory illness episodes that were accompanied by seroconversion; 
there may also be recall bias when relying on retrospective ascertainment of symptom 
episodes at our follow-ups, leading to some symptom episodes going unreported. These 
limitations arose largely due to the difficulty of sustaining participant’s motivation to 
report illness episodes over the entire study period of close to two years. However, given 
the lack of a clear influenza season in the tropics, more intensive follow-up regimens 
(such as weekly follow-up visits or even phone calls) was logistically not feasible, and 
the reliance on voluntary notification and retrospective recall of symptom episodes 
coupled with evidence of infection from serology was the best alternative. In any case, 
reduced ascertainment of these outcomes would constitute mainly a bias towards the null, 
and hence would account for the significant associations we observed between T-cell 
response and protection against influenza infection. 
 
3.5 Conclusion 
In conclusion, we found evidence of significant correlation between T-cell mediated 
immunity towards H3N2 and influenza infection, in particular for homotypic protection 
to H3N2. The effect of baseline T-cell mediated immunity was most evident in 
observations where HI titres were <20, as well as observations closer to the baseline 
sample. These findings have important implications for development of vaccine 





CHAPTER 4. CONCLUDING CHAPTER 
4.1 Summary and significance from two studies 
Chapter 2 showed that decline in antibodies to A(H1N1)pdm09 takes place as soon as six 
month to one year from the point of seroconversion; the decline is as drastic as from what 
is considered sero-protective (HI titre≥40) to a non sero-protective level (HI titre <40). 
The rate of antibody decline was more rapid in the elderly, possibly as a consequence of 
immunosenescence. Chapter 3 demonstrated the effect of pre-existing T-cell response in 
protection to homotypic and heterotypic influenza infection. There was a significant 
protective effect for both influenza infection with and without self-reported respiratory 
symptoms; the protective effect was more evident in participants with lower antibody 
titres, and there was also evidence that the effect was weaker with the passage of time 
from when the T-cell response was measured, suggesting that T-cell immunity to 
influenza also wanes, as has been demonstrated for antibody mediated immunity. 
 
4.2 Relation between the two studies 
By demonstrating the rapid decline (as soon as six months to one year) in HI titres (from 
HI ≥40 to HI <40), particularly in the elderly, chapter 2 provided a motivation for the 
study in chapter 3 to investigate an alternative means of protection, which is especially 
crucial for the elderly. The findings in chapter 2 also helped us to design the study in 
chapter 3, whereby the interval between sampling time-points were scheduled at six 
months intervals to prevent the effect of declining HI titre from interfering our results; 
our assessment for the interaction between protection and age was explored using 
findings from chapter 2 which suggested a more rapid decline with age ≥55 years. In the 
end, we did not find evidence of an interaction between age and ELISPOT response, nor 
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between age and baseline HI titres (data for the latter not shown). However, lower 
baseline HI titres were found to be associated with older age, which would be consistent 
with the phenomenon of more rapid antibody decline in the elderly (chapter 2). The 
correlations between immune markers with symptoms before and after influenza 
infections were also analysed since it was observed in chapter 2 that higher titres were 
associated with symptomatic influenza infection.  
The results in chapter 3 were found to complement findings in chapter 2 in devising 
strategies for vaccine development and vaccination schedule. The results in chapter 3 
demonstrated that pre-existing T-cell mediated immunity provides protection against 
influenza infection and should not be ignored as a correlate of protection. The evidence 
suggests T-cell responses are more crucial in individuals with lower HI titres, and it may 
hence be useful to boost T-cell mediated immunity in individuals with more rapid decay 
of influenza-specific antibodies or whose antibody response is not triggered with 
vaccination, such as the elderly. Finally, it is also evident from chapter 3 that T-cell 
mediated immunity also decays with time, and therefore more refined vaccination 
schedules should be implemented to account for the anticipated timing of influenza 
epidemics as well as the rates of decline for antibodies and T-cells. However, the rate of 
T-cell decline is not directly studied in this chapter since we only measured the baseline 
T-cell mediated immunity.  
 
4.3 Implications of findings for public health  
The findings in these two studies may have significant public health contributions in the 
planning of future strategies against influenza infection. One possible way is through 
improving our annual influenza vaccination strategies especially in older age groups. In 
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chapter 2, it was observed that the decline of influenza-specific antibody immunity is 
substantial and the decline was more drastic in the elderly; the potential impact of such a 
decline on vaccine efficacy poses a substantial risk to the elderly who are most vulnerable 
to severe influenza infection. There may hence be a need to vaccinate the elderly closer in 
time to anticipated epidemics, or vaccinate them more frequently in tropical settings like 
Singapore where influenza circulates all year round. In chapter 3, there was additional 
indirect evidence of the consequence of antibody decline, as it was observed that 
antibody immunity at baseline did not protect against influenza infection as compared to 
the antibody immunity in most recent sampling time-point. The main message of chapter 
3, however, in focussing on T-cell response, is to guide strategy for development of 
vaccines targeting the T-cell response, and how to assess the efficacy of these vaccines 
(e.g. the need to be aware of the interaction with antibody titres and the time from 
administration of the vaccine). The overall evidence from the thesis on protection 
conferred by T-cell response may also provide some support in shifting vaccine 
development towards inducing pre-existing T-cell mediated immunity. 
 
4.4 Future work 
This thesis has also provided some directions for future research on influenza 
epidemiology and immunology. Instead of a cohort from the general community, a cohort 
vaccinated against influenza could be employed to investigate the decline of influenza-
specific antibodies and T-cell responses in vaccinated individuals in Singapore with 
appropriate measurements at baseline and subsequent time points. There is also scope to 
investigate comparative T-cell responses to vaccination and natural infection, and to 
assess how these might decay over time. In addition, researchers could explore the 
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interactions between high influenza-specific antibody levels and T-cell response. For 
instance, our finding that high pre-existing T-cell response is associated with a weaker 
change in antibody titres on subsequent infection is intriguing, and has consequences for 
vaccination strategies. Does the relationship work the other way round, that is, will 
maintaining high antibody titres prevent boosting of T-cell responses? If so, is repeat 
influenza vaccination actually preventing the stimulation of T-cell response? These are 
issues that need to be resolved, and some of the investigations needed to answer these 
questions would involve a mix of methodologies from human cohorts to animal models.  
 
4.5 Conclusion 
In conclusion, a more effective vaccination strategy for protection against influenza 
infection is needed since influenza-specific antibodies at baseline were found not to be a 
reliable source of protection against influenza infection. Pre-existing T-cell mediated 
immunity was shown to confer cross-protection for symptomatic and asymptomatic 
influenza infections, and more work is needed to investigate their role and devise 
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